Online citations, reference lists, and bibliographies.
← Back to Search

Application Of RPMI 2650 As A Cell Model To Evaluate Solid Formulations For Intranasal Delivery Of Drugs.

V. S. Gonçalves, A. A. Matias, J. Poejo, A. T. Serra, C. Duarte
Published 2016 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
During the development of intranasal drug delivery systems for local/systemic effect or brain targeting, it is necessary to assess its cytotoxicity and drug transport through nasal epithelium. In order to avoid animal experiments or the use of excised tissues, in vitro cell models, such as RPMI 2650 cells, are being preferred during recent years. Nevertheless, the deposition of solid formulations into nasal cell layers with further transepithelial transport rate of drugs has been poorly studied or reported. Thus, the purpose of this work is to further investigate RPMI 2650 cell line as an effective alternative to animal tissues for solid drug-loaded formulations cytotoxicity and drug permeation studies in order to become an option as a tool for drug discovery. Furthermore, we wanted to determine the extent to which the administration of drugs in particulate forms would differ in relation to the permeability of the same compounds applied as solutions. RPMI 2650 cells were cultured in submersed or at air-liquid interface conditions and characterized regarding transepithelial electrical resistance (TEER) and production of mucus. Pure ketoprofen (used as model compound) and five formulations loaded with same drug, namely solid lipid particles (Gelucire 43/01™), structured lipid particles (Gelucire 43/01™:Glyceryl monooleate) and aerogel microparticles (Alginate, Alginate:Pectin, Alginate:Carrageenan), were evaluated with RPMI 2650 model in terms of cytotoxicity and permeability of drug (applied as solution, dispersion or powder+buffer). RPMI 2650 cells were capable to grow in monolayer and multilayer, showing the same permeability as excised human nasal mucosa for sodium fluorescein (paracellular marker), with analogous TEER values and production of mucus, as referred by other authors. None of the powders showed cytotoxicity when applied to RPMI 2650 cells. Regarding permeation of drug through cell layers, not only the form of application of powders but also their physical and chemical properties affected the final permeation of active pharmaceutical ingredient. Aerogel microparticles administered directly to the cell layer (powder+buffer) exhibited the highest permeation-enhancing effect compared to the pure drug, which can be attributed to the mucoadhesive properties of the materials composing the carriers, proving to be an attractive formulation for nasal drug delivery. According to these results, RPMI 2650 showed to be a promising alternative to ex vivo or in vivo nasal models for cytotoxicity and evaluation of drug permeability of nasal drug-loaded formulations.
This paper references
10.1007/s10616-012-9493-7
Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability
Levente Kürti (2012)
10.2147/IJN.S15881
Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model
S. Eskandari (2011)
10.1016/j.ijpharm.2016.05.010
Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells.
Anne M Dolberg (2016)
10.1016/j.ejpb.2008.09.006
The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa.
C. I. Grainger (2009)
10.3390/molecules21050658
Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells
Tamás Horváth (2016)
10.1016/j.ejps.2013.03.012
In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration.
Levente Kürti (2013)
10.3390/molecules14093754
Nasal Delivery of High Molecular Weight Drugs
Y. Ozsoy (2009)
10.1016/J.CARBPOL.2007.05.026
Viscometric study of pectin–mucin interaction and its mucoadhesive bond strength
Nartaya Thirawong (2008)
10.1007/978-1-4757-0286-6_8
Passive Absorption of Drugs in Caco-2 Cells
P. Artursson (1991)
10.1371/journal.pone.0139201
Global Food Demand Scenarios for the 21st Century
B. Bodirsky (2015)
10.1016/S0928-0987(00)00087-7
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
10.1371/journal.pone.0135690
Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro
C. Meindl (2015)
10.1016/j.ijpharm.2009.06.019
Nanoparticles for direct nose-to-brain delivery of drugs.
Alpesh Mistry (2009)
10.1039/C5RA19793G
Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment
S. Singh (2016)
The permeability of large
L. L. Greenwell (2009)
10.1016/S0378-5173(03)00039-5
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.
C. Dufès (2003)
10.1111/j.2042-7158.2012.01540.x
Cultivation of RPMI 2650 cells as an in‐vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions
S. Reichl (2012)
10.1007/s12247-015-9222-9
Influence of Dosage Form, Formulation, and Delivery Device on Olfactory Deposition and Clearance: Enhancement of Nose-to-CNS Uptake
Dipy M. Vasa (2015)
10.1016/J.IJPHARM.2005.09.013
Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies.
E. Gavini (2006)
10.1016/J.MEMSCI.2014.12.041
Filtration methodologies for the clarification and concentration of human mesenchymal stem cells
B. Cunha (2015)
10.1007/s11095-015-1804-1
Drug Permeation Characterization of Inhaled Dry Powder Formulations in Air-Liquid Interfaced Cell Layer Using an Improved, Simple Apparatus for Dispersion
Ayumu Asai (2015)
10.1021/LA0345587
Adsorption of Drugs on Silica Aerogels
I. Smirnova (2003)
10.1016/j.carbpol.2014.10.045
Polysaccharide-based aerogel microspheres for oral drug delivery.
C. García-González (2015)
10.1016/j.carbpol.2013.12.008
Carrageenan and its applications in drug delivery.
L. Li (2014)
10.1016/j.ejpb.2016.07.003
Alginate-based hybrid aerogel microparticles for mucosal drug delivery.
V. S. Gonçalves (2016)
10.1016/J.SUPFLU.2015.05.010
Preparation of macroporous alginate-based aerogels for biomedical applications
Marta Martins (2015)
10.1007/s11095-014-1494-0
The Characterization of the Human Nasal Epithelial Cell Line RPMI 2650 Under Different Culture Conditions and Their Optimization for an Appropriate in vitro Nasal Model
M. E. Kreft (2014)
10.1016/j.ejpb.2010.10.003
A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Stephanie Hein (2011)
10.1016/j.ijpharm.2015.09.035
Evaluation of the appropriate time range for estimating the apparent permeability coefficient (P(app)) in a transcellular transport study.
Kazuhisa Ozeki (2015)
10.1016/j.pharmthera.2012.03.003
Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids.
S. Grassin-Delyle (2012)
10.1211/0022357011777981
In‐vitro nasal drug delivery studies: comparison of derivatised, fibrillar and polymerised collagen matrix‐based human nasal primary culture systems for nasal drug delivery studies
R. Agu (2001)
10.1016/j.ijpharm.2015.12.046
Nanoparticle transport across in vitro olfactory cell monolayers.
O. Gartziandia (2016)
10.3929/ethz-a-001734987
Cell culture sheets to study nasal peptide metabolism
Hagen Georg Peter (1996)
10.1016/j.jbiotec.2015.02.023
Exploring continuous and integrated strategies for the up- and downstream processing of human mesenchymal stem cells.
B. Cunha (2015)
10.1016/j.tiv.2012.01.015
The effect of sucrose esters on a culture model of the nasal barrier.
Levente Kürti (2012)
10.1081/DDC-120003853
Alginate in Drug Delivery Systems
H. Tønnesen (2002)
10.1002/JPS.21031
Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies.
Shuhua Bai (2008)
10.1111/j.1365-2222.2005.02258.x
The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor‐β gene expression and protein release
R. Salib (2005)
10.1016/j.ijpharm.2015.08.026
Supercritical fluid precipitation of ketoprofen in novel structured lipid carriers for enhanced mucosal delivery--a comparison with solid lipid particles.
V. S. Gonçalves (2015)
10.1007/s13346-012-0108-9
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
P. Djupesland (2012)
Drug Permeation
A. Asai (2016)
Time- and passage
P. M. Young (2010)
10.4155/tde.14.41
The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.
P. Djupesland (2014)
10.1517/17425247.2013.790887
Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting
C. Pardeshi (2013)
10.3109/03639041003695113
Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model
M. Haghi (2010)
10.1016/j.xphs.2015.12.016
Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine.
S. Lungare (2016)
10.3109/09637486.2015.1077792
Optimization of Caco-2 and HT29 co-culture in vitro cell models for permeability studies
F. Pan (2015)
10.1016/j.etap.2011.03.006
Cadmium-induced up-regulation of aldo-keto reductase 1C3 expression in human nasal septum carcinoma RPMI-2650 cells: Involvement of reactive oxygen species and phosphatidylinositol 3-kinase/Akt.
Yoon-Jin Lee (2011)
10.1023/A:1026112107100
Serially Passaged Human Nasal Epithelial Cell Monolayer for in Vitro Drug Transport Studies
Jin-Wook Yoo (2004)
10.1016/J.MEE.2013.02.021
Sterilization on dextran-coated iron oxide nanoparticles: Effects of autoclaving, filtration, UV irradiation, and ethanol treatment
L. Li (2013)
10.1016/B978-0-08-100094-6.00006-7
Cell-based in vitro models for nasal permeability studies
Flávia Sousa (2016)
10.1016/J.TOXLET.2005.07.001
In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride.
G. Fotakis (2006)
10.1016/j.ejpb.2009.08.008
RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies.
Annette Wengst (2010)



This paper is referenced by
Development of Binary Composite Solid Microparticles for Improved Intranasal Absorption of Low Permeation Drug Molecules
Dipy M. Vasa (2017)
10.31925/FARMACIA.2018.4.2
IN VITRO CELLULAR MODELS, A RESOURCEFUL TOOL IN RESPIRATORY TOXICOLOGY
Ionel Fizeșan (2018)
10.1208/s12249-019-1517-6
Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds
Hanieh Gholizadeh (2019)
10.1016/j.ijpharm.2019.02.026
How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods
Laurent Salade (2019)
10.1124/jpet.118.254672
CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations
S. Yadav (2019)
10.1007/978-3-030-04477-0_10
Innovations in Antimicrobial Engineered Nanomaterials
M. P. Bernardo (2019)
10.1101/2020.01.09.900555
Altered polarization of PAR-2 signaling during airway epithelial remodeling
R. Carey (2020)
10.1016/j.ejpb.2018.05.009
Recent advances in carrier mediated nose‐to‐brain delivery of pharmaceutics
V. Bourganis (2018)
10.1074/jbc.RA120.012710
Polarization of protease-activated receptor 2 (PAR-2) signaling is altered during airway epithelial remodeling and deciliation
R. Carey (2020)
10.1016/j.brainresbull.2018.10.009
Evaluation of intranasal delivery route of drug administration for brain targeting
F. Erdő (2018)
10.3390/pharmaceutics11080367
Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
Simone Ladel (2019)
10.1016/j.apsb.2020.02.011
The construction of in vitro nasal cavity-mimic M-cell model, design of M cell-targeting nanoparticles and evaluation of mucosal vaccination by nasal administration
Xiaotong Yang (2020)
10.1007/s13318-017-0426-x
Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?
C. Mercier (2017)
Semantic Scholar Logo Some data provided by SemanticScholar